By Josh White
Date: Thursday 29 May 2025
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
By Benjamin Chiou
Date: Tuesday 31 Dec 2024
(Sharecast News) - Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed SRA737 product has been terminated by a biopharma company in the US.
By Josh White
Date: Monday 16 Sep 2024
(Sharecast News) - Cambridge-based biotechnology firm Sareum Holdings announced on Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its patent application concerning crystalline forms of SDC-1801.
Currency | UK Pounds |
Share Price | 20.00p |
Change Today | -1.00p |
% Change | -4.76 % |
52 Week High | 31.00 |
52 Week Low | 11.25 |
Volume | 455,276 |
Shares Issued | 137.22m |
Market Cap | £27.44m |
RiskGrade | 594 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 100,000 @ 20.75p |
16:36 | 25,000 @ 20.00p |
16:35 | 40,000 @ 20.00p |
16:35 | 10,000 @ 20.00p |
16:35 | 10,000 @ 20.00p |
You are here: research